

Notes:

1. The Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 31st August, 2015
2. Statutory Auditors have carried our a “Limited review” of the standalone financial result of the Company for the quarter ended 30th June, 2015
3. The figures for the Quarter ended March 31, 2015 are the balancing figures between audited figures in respect of full financial year ended March 31, 2015 and year to date figures upto the third quarter of that financial year.
4. Details of Number of Investor complaints for the quarter ended 30th June, 2015: beginning - NIL, received- Nil, resolved – Nil, pending- NIL as at 30th June, 2015;
5. The figures have been re-grouped, re-cast and re-arranged wherever necessary;
6. As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company’s website as well as on the stock exchanges’ websites as stated below:
www.dishmangroup.com, www.bseindia.com, and www.nseindia.com.

7. The business segments of the Company comprise the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Bulk Drugs, Intermediates, Quats, Speciality Chemicals and Traded Goods

8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co., Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as “Pharma Syn B. V.”), Cohecie Fine Chemicals B.V. (formerly known as “Dishman Holland B.V.”), Carbogen Amcis Ltd.,U.K. (formerly known as “Synprotec DCR Ltd.”), CARBOGEN AMCIS AG, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., Carbogen Amcis SAS, Dishman Middle East (FZE), Dishman Japan Limited, one joint venture Company, namely Schutz Dishman Biotech Ltd.(22.33% holding by Dishman), and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards.

On behalf of the Board of Directors

Place: Ahmedabad
Date: 31st August, 2015

Arpit Vyas
Managing Director & CFO